Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Pembrolizumab

Giant cell myocarditis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chiu C-C, et al. Immune-related giant cell myocarditis after immune checkpoint inhibitor therapy in a patient with urothelial carcinoma and myasthenia gravis. Journal of Cancer Research and Practice 10: 31-33, No. 1, Jan-Mar 2023. Available from: URL: http://www.ejcrp.org/ Chiu C-C, et al. Immune-related giant cell myocarditis after immune checkpoint inhibitor therapy in a patient with urothelial carcinoma and myasthenia gravis. Journal of Cancer Research and Practice 10: 31-33, No. 1, Jan-Mar 2023. Available from: URL: http://​www.​ejcrp.​org/​
Metadaten
Titel
Pembrolizumab
Giant cell myocarditis: case report
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38559-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Etanercept

Case report

Multiple drugs

Case report

Sirolimus